0001399529-21-000025.txt : 20210127 0001399529-21-000025.hdr.sgml : 20210127 20210127184108 ACCESSION NUMBER: 0001399529-21-000025 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210125 FILED AS OF DATE: 20210127 DATE AS OF CHANGE: 20210127 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Brown Bob D CENTRAL INDEX KEY: 0001598479 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36281 FILM NUMBER: 21561370 MAIL ADDRESS: STREET 1: 87 CAMBRIDGEPARK DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02140 FORMER NAME: FORMER CONFORMED NAME: Brown Bob DATE OF NAME CHANGE: 20140129 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Dicerna Pharmaceuticals Inc CENTRAL INDEX KEY: 0001399529 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 205993609 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 75 HAYDEN AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 BUSINESS PHONE: 617 621 8097 MAIL ADDRESS: STREET 1: 75 HAYDEN AVENUE CITY: LEXINGTON STATE: MA ZIP: 02421 4 1 wf-form4_161179085557445.xml FORM 4 X0306 4 2021-01-25 0 0001399529 Dicerna Pharmaceuticals Inc DRNA 0001598479 Brown Bob D C/O DICERNA PHARMACEUTICALS, INC. 75 HAYDEN AVENUE LEXINGTON MA 02421 0 1 0 0 Chief Scientific Ofr., EVP R&D Common Stock 2021-01-25 4 M 0 16630 9.09 A 43147 D Common Stock 2021-01-25 4 S 0 21630 25 D 21517 D Employee Stock Option (Right to Buy) 9.09 2021-01-25 4 M 0 16630 0 D 2026-01-08 Common Stock 16630.0 108370 D The Reporting Person sold an aggregate of 21,630 shares of Common Stock on January 25, 2021 (the "Shares Sold") as reported in this Form 4. The Shares Sold represent 2.15% of 1,006,767 shares of Common Stock, which is the number of shares of Common Stock owned by the Reporting Person prior to the Shares Sold transaction reported in this Form 4, as well as shares issuable upon exercise or settlement of vested and unvested options and restricted stock units held by the Reporting Person as of the date of this report. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 10, 2020. As of the transaction date, the option was fully vested. The option vested in 48 monthly installments over the four-year period with a vesting start date of January 8, 2016, subject in each case to the Reporting Person's continued employment or service with the Issuer through each applicable vesting date. /s/ Douglas W. Pagan, attorney-in-fact 2021-01-27